CD274 and neoplasm: Atezolizumab studies (Phase III RCTs) utilized VENTANA PD-L1 (SP142) assay assessing the PD-L1 expression on immune cells (IC) alone as the phase I trial had revealed a significant improvement based on the PD-L1 expression on immune cells and not tumor cells (TC) (15, 16, 18).